Bioform Medical  (BFRM) Trade Now »     Rate BFRM  -  Discuss BFRM  -  Add to Watch List        

Home

Analysis & Videos

Quotes

Bull or Bear

Discuss

BFRM: Bull or Bear?

From:    SocialPicks  |  Blogsphere  |  All

SocialPicks Community

FDA Calendar Updates: ARDM, BFRM, CRTX, MDT, Zogenix BFRM

73%

+50.82% in 118 days <> Below is a summary of updates to the <font> BioMedReports.com FDA Calendar </font> , which includes a database of 260 entries as of 7/16/09. The calendar was originally created by Mike Havrilla to track companies with pending new drug, biological agent, or medical device new product decisions at the FDA. With the launch of <font> BioMedReports.com </font> , the FDA Calendar has expanded to include the following categories: pending new submissions to the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, sBLA filings), pending complete response letter (CRL) re-submissions to the FDA, and pendin... Continue reading »

Extreme FDA Medical Device Trades: 7 Stocks Under $5 BFRM

73%

+17.87% in 11 days (closed on 07/16/09) <> Below are extreme trades among companies with stock prices under $5 from the <font> BioMedReports.com FDA Calendar </font> , which includes 238 entries as of 7/5/09. The calendar was originally created by Mike Havrilla to track companies with pending new drug, biological agent, or medical device new product decisions at the FDA. With the launch of <font> BioMedReports.com </font> , the FDA Calendar has expanded to include the following categories: pending new submissions to the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, sBLA filings), pending complete response letter (CRL) re-submissio... Continue reading »

FDA, Clinical Trial Calendars: Nine Cash Plus Catalyst Trades BFRM

73%

+60.47% in 57 days (closed on 07/05/09) Below are nine 'Cash Plus Catalyst' trades which include companies that are currently trading for around 2X net cash/equivalents or less (the ratio of market cap to cash/equivalents less debt) with pending FDA decisions, clinical trial results, or pending FDA submissions. <font> Click here for a link </font> to the BioMedReports FDA and Clinical Trial Calendars page.   <> 1.) BioForm Medical (NASDAQ:BFRM) : Market Cap = $59.8M, Net Cash = $41.4M. In March 2009, BioForm Medical announced the results of a clinical trial evaluating the mixing of lidocaine with RADIESSE derma... Continue reading »

From the Blogosphere

Analyst upgrades, downgrades and initiations: ART, BBY, HEV, NVDA, OSG, RDS.A ...

Filed under: Analyst reports, Analyst upgrades and downgrades, Best Buy (BBY), Analyst initiations Analyst upgrades: <> FBR Capital upgraded Overseas Shipholding (NYSE: OSG) to Outperform from Market Perform following the Q3 results as it believes the worst quarters are behind the company. The firm raised its target on shares to $48 from $35. Deutsche Bank upgraded Corporate Executive Board (NASDAQ: EXBD) to Hold from Sell following the Q3 results to reflect the company's lower costs. The firm raised its target on shares to $22 from $18. <>RBC Capital upgraded Enbridge (NYSE: EEQ) to S... Continue reading »

FDA Calendar: New Entries, One-Week Outlook

73%

The accompanying table (click to enlarge) includes 84 pending FDA new product decision dates. Click here for a link to my previous calendars and here for 16 extreme FDA trades of companies with market caps below $150M with pending decisions. Click here for a calendar of 89 clinical trial result estimates along with pending FDA new filings or re-submissions for regulatory approval. New Entries on the FDA Calendar: 1.) Acorda Therapeutics (ACOR): ACOR filed a NDA for Fampridine-SR Oral Tablet to improve the walking ability of people with multiple sclerosis (MS) with a standard review expected a... Continue reading »

52 Week Low's 2/1

2 %

(URX)= United Refining Energ ... (UNCA )= Unica Corp (TXA )= Tribune Co New (PCOP )= Pharmacopeia Inc (PCBI )= Peoples Cmnty Bancorp Inc (OMRI )= Omrix Biopharmaceutic ... (MRX)= Medicis Pharmaceutica ... (MROE )= Monroe Bancorp (MAYS )= J W Mays Inc (LIMC )= Limco Piedmont Inc (KWK )= Quicksilver Resources Inc (INTT )= Intest Corp (BFRM )= Bioform Medical Inc (BCRX )= BioCryst Pharmaceutic ... (AZN )= Astrazeneca Plc (AWBC )= Americanwest Bancorpo ... (AVID )= Avid Technology Inc (ARAY )= Accuray Inc ? Grab this Headline Animator Visit the ValuePlays Bookstore for Great Investing Books <><>Ente... Continue reading »

52 Week Low's 2/1

(URX)= United Refining Energ ... (UNCA )= Unica Corp (TXA )= Tribune Co New (PCOP )= Pharmacopeia Inc (PCBI )= Peoples Cmnty Bancorp Inc (OMRI )= Omrix Biopharmaceutic ... (MRX)= Medicis Pharmaceutica ... (MROE )= Monroe Bancorp (MAYS )= J W Mays Inc (LIMC )= Limco Piedmont Inc (KWK )= Quicksilver Resources Inc (INTT )= Intest Corp (BFRM )= Bioform Medical Inc (BCRX )= BioCryst Pharmaceutic ... (AZN )= Astrazeneca Plc (AWBC )= Americanwest Bancorpo ... (AVID )= Avid Technology Inc (ARAY )= Accuray Inc ? Grab this Headline Animator Visit the ValuePlays Bookstore for Great Investing Books <><>Ente... Continue reading »

... more »  

None of the information contained on SocialPicks.com constitutes a recommendation by SocialPicks or its users that any particular security, portfolio of securities, transaction, or investment strategy is suitable for any specific person. SocialPicks is not responsible for the posts, discussions, and recommendations of the users on the Site. SocialPicks does not provide investment advice. You must make your own independent decisions regarding any security, portfolio of securities, transaction, or investment strategy mentioned on the website. SocialPicks' users' past results are not necessarily indicative of future performance. Neither SocialPicks nor any of its users guarantees any specific outcome or profit, and you should be aware of the real risk of loss in following any strategy or investments discussed on the website. You understand and agree that you use the Site and Services at your own discretion and risk and that you will be solely responsible for any damages that arise from such use. Before acting on any information contained on the website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.